Category: Bio & Healthcare

Brokerage : Daishin Securities Analyst : Kahye Hong Investment Rating : BUY (Maintained) Target Price : KRW 410,000 (Upgraded) Core Momentum : Inflow of recurring commercial milestones driven by expanding Keytruda Qlex adoption, complemented by platform extension into next-generation modalities like RNA and new licensing catalysts. 📊 1. [Valuation & Key Financial Metrics] 🚀 2….

Read More “[Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10” »

Brokerage : Daishin Securities Analyst : Kahye Hong Investment Rating : BUY (Maintained) Target Price : KRW 410,000 (Upgraded) Core Momentum : Inflow of recurring commercial milestones driven by expanding Keytruda Qlex adoption, complemented by platform extension into next-generation modalities like RNA and new licensing catalysts. 📊 1. [Valuation & Key Financial Metrics] 🚀 2….

Read More “[Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10” »

Brokerage : Shinhan Securities Analyst : Minyong Eom, Seokhyeon Yoon Investment Rating : BUY (Maintained) Target Price : KRW 480,000 (Upgraded) Core Momentum : First Kosdaq biotech to execute 3 global pharma L/O deals in a single year (KRW 1.8 Trillion combined), paired with Keytruda SC conversion tracking faster than market expectations and extensive H2…

Read More “[Research] Alteogen (196170) – Shinhan Securities | Record 3 Out-Licensing Deals in 2026 · Rapid Keytruda SC Rollout · H2 Clinical Pipeline Catalysts / 2026-08-06” »

Brokerage : Hana Securities Analyst : Seona Kim (RA: Heekyung Lee) Investment Rating : BUY (Maintained) Target Price : KRW 580,000 (Maintained) Core Momentum : Execution of a USD 365 Million ALT-B4 out-licensing deal validates sustained platform demand, while surging Keytruda Qlex sales drive upward revisions to medium-term revenue forecasts. 📊 1. [Valuation & Key…

Read More “[Research] Alteogen (196170) – Hana Securities | New ALT-B4 Deal Signed · Qlex Prescription Surge · SC Conversion Acceleration / 2026-08-06” »

Brokerage : SK Securities Analyst : Seonkyoung Lee Investment Rating : BUY (Maintained) Target Price : KRW 247,823 (Maintained) Core Momentum : Operating leverage begins in earnest as high-margin new products expand to 65% of total sales, delivering a strong 2Q26 earnings beat with sustained growth expected from Zymfentra’s Pfizer collaboration and Omlyclo’s US launch….

Read More “[Research] Celltrion (068270) – SK Securities | 2Q26 Re: Profitability Inflection Underway · Operating Leverage In Focus · Robust H2 Momentum / 2026-08-03” »

Brokerage : iM Securities Analyst : Jae-won Jeong Investment Rating : Buy (Maintained) Target Price : KRW 260,000 (Maintained) Core Momentum : Quality of earnings improving through the expanding sales mix of lower-cost-ratio new products and long-term execution of the two-track biosimilar and novel drug strategy 📊 1. [Valuation & Key Financial Metrics] 🚀 2….

Read More “[Research] Celltrion (068270) – iM Securities | New Product Mix Expansion · First-Mover Advantage · Two-Track Long-Term Strategy / 2026-07-28” »

Brokerage : Shinhan Securities Analyst : Ho-chul Lee, Min-yong Eom Investment Rating : BUY (Maintained) Target Price : KRW 290,000 (Raised) Core Momentum : Entering a virtuous cycle where expanding North American new product sales and a 2030 portfolio of 18 biosimilars support proprietary new drug development 📊 1. [Valuation & Key Financial Metrics] 🚀…

Read More “[Research] Celltrion (068270) – Shinhan Securities | North American New Product Penetration · 2030 Pipeline · New Drug Cycle / 2026-07-28” »

Brokerage : Mirae Asset Securities Analyst : Seung-min Kim Investment Rating : BUY (Maintained) Target Price : KRW 280,000 (Raised) Core Momentum : Earnings estimate upgrades driven by stronger-than-expected profitability contributions from new biosimilars and favorable valuation vs global peers supported by in-house cost efficiency 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market…

Read More “[Research] Celltrion (068270) – Mirae Asset Securities | New Product Mix Expansion · In-House Cost Efficiency · Valuation vs Peers / 2026-07-28” »

Brokerage : Daishin Securities Analyst : Kahye Hong Investment Rating : BUY (Maintained) Target Price : KRW 280,000 (Maintained) Core Momentum : H2 margin expansion driven by European tender shipments and new product mix, alongside upcoming clinical milestones for the new drug pipeline 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities &…

Read More “[Research] Celltrion (068270) – Daishin Securities | New Product Mix · H2 Margin Expansion · New Drug Pipeline / 2026-07-28” »

Brokerage : Yuanta Securities Analyst : Hyun-soo Ha Investment Rating : BUY (Maintained) Target Price : KRW 280,000 (Raised) Core Momentum : Rapid revenue growth in new biosimilars driving profitability improvement and pipeline expansion sustaining mid-to-long-term earnings growth 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities & Business Outlook] 📝 Editor’s Comment…

Read More “[Research] Celltrion (068270) – Yuanta Securities | New Product Mix Expansion · Pipeline Addition · Earnings Growth / 2026-07-28” »